Synthesis and anti-norovirus activity of pyranobenzopyrone compounds by Pokhrel, Laxman et al.
This is the author’s final, peer-reviewed manuscript as accepted for publication.  The 
publisher-formatted version may be available through the publisher’s web site or your 
institution’s library.  
This item was retrieved from the K-State Research Exchange (K-REx), the institutional 
repository of Kansas State University.  K-REx is available at http://krex.ksu.edu 
 
 
Synthesis and anti-norovirus activity of pyranobenzopyrone compounds 
 
 
Laxman Pokhrel, Yunjeong Kim, Thi D. T. Nguyen, Allan M. Prior, Jianyu Lu, 
Kyeong-Ok Chang, and Duy H. Hua 
 
 
 
How to cite this manuscript 
 
If you make reference to this version of the manuscript, use the following information: 
 
Pokhrel, L., Kim, Y., Nguyen, T. D. T., Prior, A. M., Lu, J., Chang, K., & Hua, D. 
H. (2012).  Synthesis and anti-norovirus activity of pyranobenzopyrone 
compounds. Retrieved from krex.ksu.edu 
 
 
 
Published Version Information 
 
 
Citation: Pokhrel, L., Kim, Y., Nguyen, T. D. T., Prior, A. M., Lu, J., Chang, K., & 
Hua, D. H. (2012).  Synthesis and anti-norovirus activity of pyranobenzopyrone 
compounds.  Bioorganic & Medicinal Chemistry Letters, 22(10), 3480-3484. 
 
 
Copyright: © 2012 Elsevier Ltd. 
 
 
Digital Object Identifier (DOI): doi: org/10.1016/j.bmcl.2012.03.084 
 
 
Publisher’s Link: http://www.sciencedirect.com/science/journal/0960894X/22/10 
 
 
1 
 
Synthesis and Anti-norovirus Activity of Pyranobenzopyrone Compounds 
 
Laxman Pokhrel,a Yunjeong Kim,b Thi D. T. Nguyen,a Allan M. Prior,a Jianyu Lu,a Kyeong-Ok 
Chang,b and Duy H. Hua*a 
aDepartment of Chemistry, Kansas State University, Manhattan, KS  66506 
bDepartment of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas 
State University, Manhattan, KS  66506 
 
*Corresponding author: Tel.: 785-532-6699; Fax: 785-532-6666; E-mail: duy@ksu.edu (D. H. 
Hua) 
 
Abstract 
During the last decade, noroviruses have gained media attention as the cause of large 
scale outbreaks of gastroenteritis on cruise ships, dormitories, nursing homes, etc.  Although 
noroviruses do not multiply in food or water, they can cause large outbreaks because 
approximately 10 - 100 virions are sufficient to cause illness in a healthy adult.  Recently, it was 
shown that the activity of acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT1) enzyme may 
be important in norovirus infection.  In search of anti-noroviral agents based on the inhibition of 
ACAT1, we synthesized and evaluated the inhibitory activities of a class of pyranobenzopyrone 
molecules containing amino, pyridine, substituted quinolines, or 7,8-benzoquinoline nucleus.  
Three of the sixteen evaluated compounds possess ED50 values in the low M range.  2-
Quinolylmethyl derivative 3A and 4-quinolylmethyl derivative 4A showed ED50 values of  3.4 
2 
 
and 2.4 M and TD50 values of >200 and 96.4 M, respectively.  The identified active 
compounds are suitable for further modification for the development of anti-norovirus agents. 
 
Key words:  acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT1), caliciviruses, norovirus, 
anti-noroviruses, pyranobenzopyrones. 
 
Noroviruses, category B bioterrorism agents, are the leading cause of food- or water-
borne gastroenteritis outbreaks. Studies have shown that noroviruses are responsible for 
approximate 90% of epidemic non-bacterial food-water-borne gastroenteritis outbreaks with an 
estimated 23 million cases annually in the US causing 50,000 hospitalizations and 300 deaths.1-3 
Norovirus belongs to the Caliciviridae family, and may infect an individual with as few as 10 
viral particles.  Outbreaks often occur in closed environments such as dormitories, cruise ships, 
hospitals, and care facilities.  Caliciviruses (Family Caliciviridae) are small, non-enveloped 
RNA viruses of 27-35 nm in diameter. They possess a single-stranded, plus-sense genomic RNA 
of 7-8 kb, which encodes a nonstructural polyprotein, a major structural capsid protein of 58-80 
kD (VP1), and a small basic protein (VP2).4  Currently, there are no specific drugs for norovirus 
infection. Vaccine development for human noroviruses have faced challenges because 
noroviruses do not grow in cell culture, show high diversity, and immunity from heterologous 
strains do not seem to confer protection.5  Furthermore, repeat infections in adults indicate that 
long-term immunity may be absent.  Consequently there is an urgent need for the development of 
effective anti-noroviral drugs.  The recent development of replicon-harboring cells for 
norovirus6,7 has made possible the study of norovirus replication in cells.  DNA microarray 
analysis of norovirus replicon-harboring cells (HG23) by an Affymetrix Gene Chip showed the 
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up regulations of acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT1) and other cholesterol 
modulating genes (> ±1.5 fold).9 Moreover, commercially available ACAT inhibitors were 
shown to inhibit norovirus replication.9 These findings suggest that cellular ACAT may be a 
potential therapeutic target for norovirus infection. Previously, we reported a class of 
pyranobenzopyrones that possesses ACAT inhibitory activity.10 Hence, anti-norovirus activities 
of pyranobenzopyrones were investigated.  Herein, we report the synthesis and anti-norovirus 
activity of a small library of sixteen pyranobenzopyrones containing amino, pyridine, quinoline, 
and 7,8-benzoquinoline nucleus (Figure 1).  Among the pyranobenzopyrones, several 
compounds possess anti-norovirus activity in low micromolar concentrations in vitro with 
therapeutic index values of > 40. 
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Figure 1.  Synthesized and Bioevaluated Pyranobenzopyran Compounds 1 - 8.
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The synthesis of pyranobenzopyrones 1 – 7 stems from a reductive amination reaction11 
of amine 10 and various aldehydes, 11 – 17 as depicted in Scheme 1.  Initially, amine 10 was 
prepared via a four-step sequence of reactions starting from pyranobenzopyrones 9 by 
hydroboration-hydroxylation reaction followed by mesylation, displacement with sodium azide, 
and reduction with H2/Pd.10  The synthesis was simplified by a one-pot hydroboration-amination 
reaction of 9 with BH3•THF followed by hydroxylamine-O-sulfonic acid12 in 50% yield (Scheme 
1).  A mixture of two diastereomers in a ratio of 1:1 resulted at the newly created carbon center 
C12 from the hydroboration reaction indicated by its 1H and 13C NMR spectra.  The 
diastereomers are separable by HPLC but not silica gel column chromatograph.  Alkylation of 
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amine 10 with 1 equivalent each of aldehydes 11 – 17 separately in methanol followed by 
sodium cyanoborohydride afforded amines 1 – 7, respectively.  Yields of compounds 1 - 7 range 
from 47 – 66%.  Pyridinecarboxaldehydes, various substituted quinolinecarboxaldehydes, and 
7,8-benzoquinoline-4-carboxaldehyde (17 or 4-azaphenanthrene-1-carboxaldehyde) were used in 
the reductive amination reaction, and functional groups such as primary alcohol, ester, and 
trioxane are stable under the reaction conditions. 
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Scheme 1.  Synthesis of Compounds 1 - 7.
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Amide 8 was synthesized from the coupling reaction of quinoline-4-carboxylic acid (18), 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and amine 10 in 65% yield (Scheme 2).  
Aldehydes 11, 12, and 13A and carboxylic acid 18 along with various methylquinolines were 
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obtained from commercial sources.  Aldehydes 14A, 15, and 16 were prepared by benzylic 
oxidation with selenium dioxide13 or bromination followed by hydrolysis/oxidation14 of 
methylquinolines, and aldehydes 13B, 13C, 14B - 14F, and 17 were achieved from free-radical 
heteroaromatic trioxanylation15,16 with trioxane-t-BuOOH-ferrous sulfate (Schemes 2 – 4).  
Hence, oxidation of 4-methylquinoline (19) with SeO2 under refluxing toluene gave quinoline-4-
carboxaldehyde (14A) in 73% yield along with a small amount of over oxidized carboxylic acid 
18 (Scheme 2).  Similarly, quinoline-6-carboxaldehyde (15) was obtained from 6-
methylquinoline (20) in 54% yield after the treatment with SeO2 in refluxing xylene.  To our 
surprise, oxidation of 8-methylquinoline (21) under similar reaction conditions provided only a 
trace amount of 8-quinoline-carboxaldehyde (16).  Apparently, methyl group appended on ring A 
of quinoline is activated toward oxidation, but methyl group on ring B is not, and a sluggish 
oxidation resulted.  To overcome the problem, benzylic bromination of 21 was carried out.  
Treatment of 21 with N-bromosuccinimide (NBS) and a catalytic amount of 
azobisisobutyronitrile (AIBN) followed by aqueous hydrolysis accompanying air oxidation gave 
aldehyde 16 (37% yield)14 along with the hydrolyzed product, 6-hydroxymethylquinoline (22) 
(53% yield).  Oxidation of alcohol 22 with o-iodoxybenzoic acid (IBX) and DMSO17 furnished 
16 in a 79% yield.  
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Scheme 2.  Syntheses of Compound 8 and quinolinecarboxaldehydes 14A, 15, and 16.
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Substituted quinolinecarboxaldehydes 13B, 13C, 14B - 14F,  and 7,8-
benzoquinolinecarboxaldehyde (17) were obtained from heteroaromatic trioxanylation reactions 
(Schemes 3 and 4).15,16 Treatment of 2-methylquinoline (23) with trioxane, t-butyl hydroperoxide 
and trifluoroacetic acid (TFA) in the presence of a catalytic amount of ferrous sulfate afforded 
trioxanylquinoline 24, which underwent acidic hydrolysis to give aldehyde 14B.  2-
Hydroxymethyl-4-quinolinecarboxaldehyde (14D) was obtained from the benzylic oxidation of 
24 with selenium dioxide followed by the hydrolysis of the resulting trioxanyl aldehyde 25 with 
2 N HCl to give dialdehyde 26.  Subsequent reduction of 26 with sodium borohydride afforded 
14D.  In the reduction process, regioisomer, 4-hydroxymethyl-2-quinolinecarboxaldehyde (27) 
and 2,4-di(hydroxymethyl)quinoline (28) were also isolated.  Acetylation of the hydroxyl 
function of 14D with acetic anhydride and zinc oxide18 produced acetate 14C (Scheme 3).  
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Scheme 3.  Syntheses of quinolinecarboxaldehydes 14B - 14D.
+
Ac2O
ZnO
(85% yield)
24
SeO2
toluene
80oC
N
2
O
O
O
25
2 N HCl
26O
H
N
HO
O
H
(68% overall yield)
26
NaBH4
CH2Cl2/EtOH
27
N
HO
O
H
(35% yield)
(32% yield)
+
28
N
HO
OH
(16% yield)
Me N
2
23
FeSO4, TFA
t-BuOOH
trioxane
(51% yield) Me N
2
24
O
O
O 10% H2SO4
reflux
(79% yield)
14B
14D
14D 14C
 
 
 Similar trioxanylation of 4-methylquinoline (19) furnished 2-trioxanequinoline 29 in 43% 
yield along with a small amount of 4-methyl-2-quinolinecarboxaldehyde (13B) (3% yield), 
which derived from the hydrolysis of the trioxane moiety of 29 with TFA and water in the 
reaction mixture (Scheme 4).  Alternatively, aldehyde 13B can be achieved in 50% yield from a 
two-step trioxanylation of 19 followed by acidic hydrolysis with 10% aqueous sulfuric acid of 
the resulting trioxane without purification.  2-Trioxanyl-4-carboxaldehyde (14E) was obtained 
from the benzylic oxidation of 29 with selenium dioxide.  Similar to the selenylation reaction of 
8-methylquinoline (21), trioxanylation of 6-methylquinoline (20) appeared to be sluggish.  
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Hence, the reaction of 20 with trioxane, t-butyl hydroperoxide, TFA and ferrous sulfate followed 
by acidic hydrolysis furnished a mixture of regioisomers, 6-methyl-4-carboxaldehyde (14F) 
(17% yield) and 6-methyl-2-carboxaldehyde (13C) (16% yield), which were separated by silica 
gel column chromatography.  The spectral data of compound 13C are similar to that reported,19 
and the assignment of regiochemistry of 14F is based on its 1H NMR spectral data.  The 
chemical shift of C2-H of 14F appears at  9.14 ppm as a doublet with coupling constant J value 
of 4.3 Hz, and that of C3-H at  7.77 ppm as a doublet with J value of 4.3 Hz, which are similar 
to that of 4-quinolinecarboxaldehyde (14A).  Formylation of 4-azaphenanthrene (30) under 
similar reaction conditions followed by hydrolysis with 2 N HCl afforded 7,8-benzoquinoline-4-
carboxaldehyde (17).  Hence, methylquinolines can either be oxidized to the corresponding 
quinolinecarboxaldehydes or formylated to methylquinolinecarboxaldehydes. 
 
Scheme 4.  Syntheses of quinolinecarboxaldehydes 13B, 13C, 14E, 14F and 7,8-benzoquinolinecarboxaldehyde (17).
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From our initial screening of the effects of pyranobenzopyrone compounds on the 
reduction of NV replicon-harboring cells (HG23 cells), 3-pyridyl analog 1 showed promising 
results with ED50 value (effective dosage at reducing NV genome levels by 50% at 24 h post-
treatment) and TD50 value (cytotoxic dosage in killing 50% HG23 cells at 48 h post-treatment 
determined by cytotoxicity assay at 48 h of treatment)7,9,20 of  4 and >200 M, respectively.  
Hence, a small library of pyridylmethyl, quinolylmethyl, quinolylcarbonyl, and 4-
azaphenanthrenylmethyl derivatives along with their synthetic precursor, amine 10, was 
evaluated for their anti-norovirus activities.  Results of the inhibition of NV RNA replication are 
summarized in Table 1.  To our surprise, amine 10, 4-pyridylmethyl 2, 8-quinolylmethyl 6, and 
2-acetoxymethyl- and 2-hydroxymethyl-4-quinolylmethyls 4C and 4D have ED50 values >10 
M.  Due to high ED50 values, TD50 values of these compounds were not determined except 
compound 10.  Other quinolylmethyl, substituted quinolylmethyl, and 4-azaphenanthrenylmethyl 
derivatives along with 4-quinolyl amide 8 possess ED50 values ranging from 2 – 8 M and TD50 
values of 61 – >200 M.  In particular, 2-quinolylmethyl 3A, 4-quinolylmethyl 4A, and 6-
methyl-4-quinolylmethyl 4F possess the strongest anti-norovirus activities with respective ED50 
values of 3.4, 2.4, and 3.4 M and TI (therapeutic index; derived from TD50/ED50) values of 
58.8, 40.2, and 18.0, respectively.  6-Methyl-2-quinolylmethyl 3C on the other hand showed a 
lower ED50 value of 8.1 M.  Hence, addition of substituent at C6 or ring B of 4-quinolylmethyl 
analog appears to retain its antiviral activity and substituent on ring A diminishes its activity. 
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Table 1.  Effects of pyranobenzopyrone compounds on the reduction of NV RNA replication 
(ED50) and toxicity (TD50) in HG23 cells (NV replicon-haboring cells) and their therapeutic 
indexes (TI). 
 
Compound ED50 value in µM TD50 value in µM Therapeutic index (TI) 
1 
2 
3A 
4A 
5 
6 
4B 
4C 
4D 
4E 
3B 
4.1 
9.6 
3.4 
2.4 
8.1 
>10 
8.2 
9.7 
9.5 
8.4 
5.3 
>200 
ND* 
>200 
96.4 
ND 
>160 
ND 
ND 
ND 
ND 
>200 
>50 
 - 
>58.8 
40.2 
 - 
>16 
 - 
- 
- 
- 
>40 
4F 3.4 61.2 18.0 
3C 8.1 83.7 10.3 
7 5.3 >200 >40 
8 
10                                        
5.5 
>10 
103.5 
>200 
18.8 
- 
 
* ND: not determined due to high ED50 values. Each value is the average of at least 2 
independent tests. 
 
In conclusion, various pyranobenzopyrone molecules containing pyridine, quinoline, or 
4-azaphenanthrene nucleus were synthesized and evaluated.  4-Quinolylmethyl analogs 4A and 
4F and 2-quinolylmethyl analog 3A possess the strongest anti-norovirus activities having ED50 
12 
 
values of 2.4 – 3.4 M and TI values of 18.0 – >58.8.  The identified hits are suitable for further 
optimization via medicinal chemistry and molecular modeling. 
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Supplemental Materials. 
Experimental Section. 
I.  General Methods.  NMR spectra were obtained from a 400-MHz spectrometer (Varian Inc.), 
in CDCl3, unless otherwise indicated, and reported in ppm.  Infrared spectra were taken from a 
Nicolet 380 FT-IR instrument (Thermo Scientific) in solid forms and are reported in wave 
numbers (cm
-1
).  Low-resolution mass spectra were taken from an API 2000-triple quadrupole 
ESI-MS/MS mass spectrometer (from Applied Biosystems).  High-resolution Mass spectra were 
obtained from a LCT Premier (Waters Corp., Milford MA) time of flight mass spectrometer.  
The instrument was operated at 10,000 resolution (W mode) with dynamic range enhancement 
that attenuates large intensity signals.  The cone voltage was 60 eV.  Spectra were acquired at 
16666 Hz pusher frequency covering the mass range 100 to 1200  and accumulating data for 2 
seconds per cycle.  Mass correction for exact mass determinations was made automatically with 
the lock mass feature in the MassLynx data system.  A reference compound in an auxiliary 
sprayer is sampled every third cycle by toggling a “shutter” between the analysis and reference 
needles.  The reference mass is used for a linear mass correction of the analytical cycles.  
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Chemicals such as sodium cyanoborohydride, 4-hydroxy-6-methyl-2-pyrone, (S)-perillaldehyde, 
hydroxylamine-O-sulfonic acid, pyridine-3-carboxaldehyde (11), pyridine-4-carboxaldehyde 
(12), 2-quinolinecarboxaldehyde (13A) and 4-quinolinecarboxylic acid (18) were purchased 
from Fisher Scientific and Aldrich Chemical Co.  (5aS,7S)-{7-Isopropenyl-3-methyl-1H,7H-
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (9) was prepared as described.21 
II.1. (5aS,7S)-7-[(1R) and (1S)-2-Amino-1-methylethyl)-3-methyl-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (10).  To a cold (0oC) solution of 5.0 g (19.4 
mmol) of compound 9 in 100 mL of THF under argon was added 10 mL (9.7 mmol) of 
BH3•THF complex (1.0 M in THF) dropwise.  After stirring the solution at 0oC for 2 h and 25oC 
for 12 h, the borane solution was added to 3.3 g (29.2 mmol) of hydroxylamine-O-sulfonic acid 
under argon via a cannula followed by the addition of 20 mL of chloroform.  The reaction 
mixture was heated to reflux for 7 h, cooled to 25oC, diluted with 300 mL of ethyl acetate, and 
extracted with 2 N HCl (100 mL each) twice.  The combined HCl layer was washed three times 
with ethyl acetate (100 mL each), basified carefully with 5% sodium carbonate until pH = 9 ~ 
10, and extracted three times with dichloromethane.  The combined dichloromethane layer was 
washed with brine, dried (anhydrous Na2SO4), and concentrated to give 2.7 g (50% yield) of 
compound 10, whose 1H and 13C NMR spectra are identical to that reported.10  
 
General procedure for the synthesis of compounds 1 – 7 via the reductive amination 
reaction. 
 
II.2. (5aS,7S)-3-Methyl-7-(1-(pyridin-3-ylmethylamino)propan-2-yl)-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (1).  A solution of 85 mg (0.31 mmol) of amine 
10 and 33 mg (0.31 mmol) of 3-pyridinecarboxaldehyde (11) in 5 mL of dry MeOH was stirred 
under argon at 25oC for 12 h, added acetic acid (5 drops) and a solution of 68 mg (1.1 mmol) of 
3 
 
NaBH3CN in methanol.  After stirring for 1 h, the reaction solution was diluted with 40 mL of 
5% aqueous ammonium hydroxide and extracted three times with dichloromethane, and the 
combined organic layer was washed with brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a gradient mixture of CH2Cl2 and MeOH as eluant to give 
68 mg (60% yield) of 1 as a solid.  1H NMR δ 8.57 (s, 1 H), 8.51 (d, J = 4 Hz, 1 H), 7.70 (d, J = 
7.5 Hz, 1 H), 7.28 (dd, J = 7.5, 4 Hz, 1 H), 6.05 (s, 1 H), 5.71 (s, 1 H), 5.11 – 4.98 (m, 1 H), 3.81 
(s, 2 H), 2.67 – 2.57 (m, 1 H), 2.53 – 2.38 (m, 2 H), 2.19 (s, 3 H), 2.08 – 1.91 (m, 2 H), 1.74 – 
1.46 (m, 4 H), 1.29 – 1.06 (m, 1 H), 0.91 (d, J = 5.0 Hz, 3 H); 13C NMR δ 163.3, 162.6, 161.6, 
149.7, 148.5, 136.0, 135.6, 132.8, 123.5, 109.1, 99.9, 97.4, 79.7, 79.5, 53.1, 53.05, 51.5,  39.2, 
38.7, 38.5, 37.7, 37.6, 36.7, 32.4, 32.3, 31.0, 28.4, 20.2, 14.7, 14.6;  MS (electrospray ionization) 
m/z 367.2 (M+H+); HRMS calcd for C22H27N2O3+ (M+H+) 367.2022, found 367.2017 (100%). 
II.3. (5aS,7S)-3-Methyl-7-(1-(pyridin-4-ylmethylamino)propan-2-yl)-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (2).  From 85 mg (0.31 mmol) of amine 10 and 
33 mg (0.31 mmol) of 4-pyridinecarboxaldehyde (12), 72 mg (64% yield) of compound 2 was 
obtained as a solid.  1H NMR δ 8.54 (d, J = 4.5 Hz, 2 H), 7.26 (d, J = 4.7 Hz, 2 H), 6.06 (s, 1 H), 
5.70 (s, 1 H), 5.11 – 4.98 (m, 1 H), 3.80 (s, 2 H), 2.63 – 2.55 (m, 1 H), 2.50 – 2.39 (m, 2 H), 2.18 
(s, 3 H), 2.09 – 1.91 (m, 2 H), 1.75 – 1.47 (m, 4 H), 1.35 – 1.05 (m, 1 H), 0.92 (d, J = 6.6 Hz, 3 
H); 13C NMR δ 163.3, 163.3, 162.6, 161.6, 149.8, 132.8, 123.1, 109.3, 99.9, 97.4, 79.7, 79.6, 
53.4, 53.3, 53.0, 39.3, 38.8, 38.7, 38.0, 37.9, 36.9, 32.5, 32.4, 31.1, 28.6, 20.2, 14.8, 14.7;  MS 
(electrospray ionization) m/z 367.2 (M+H+), 139.0, 121.2; HRMS calcd for C22H26N2O3Na+ 
(M+Na+) 389.1841, found 389.1844 (100%). 
II.4. (5aS,7S)-3-Methyl-7-(1-(quinolin-2-ylmethylamino)propan-2-yl)-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (3A).  From 60 mg (0.22 mmol) of amine 10 
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and 35 mg (0.22 mmol) of 2-quinolinecarboxaldehyde (13A), 54 mg (60% yield) of 3A was 
obtained as a solid.  1H NMR δ 8.11 (d, J = 8.6 Hz, 1 H), 8.04 (d, J = 8.2 Hz, 1 H), 7.79 (d, J = 
8.2 Hz, 1 H), 7.69 (t, J = 7.4 Hz, 1 H), 7.50 (t, J = 7.4 Hz, 1 H), 7.43 (d, J = 8.6 Hz, 1 H), 6.04 (s, 
1 H), 5.67 (s, 1 H), 5.08 – 5.00 (m, 1 H), 4.09 (s, 2 H), 2.69 (dd, J = 11.7, 5.8 Hz, 1 H), 2.59 – 
2.50 (m, 1 H), 2.41 (d, J = 14 Hz, 1 H), 2.16 (s, 3 H), 2.10 – 1.91 (m, 2 H), 1.78 – 1.45 (m, 4 H), 
1.27 – 1.04 (m, 1 H), 0.93 (d, J = 6.2 Hz, 1.5 H, CH3), 0.92, (d, J = 6.2 Hz, 1.5 H, CH3) (2 
diastereomers at C12); 13C NMR δ 163.4, 163.4, 162.7, 161.6, 160.1, 147.8, 136.6, 133.0, 132.9, 
129.7, 129.0, 127.7, 127.5, 126.3, 120.7, 109.2, 99.9, 97.5, 79.8, 79.7, 55.9, 53.7, 53.6, 39.3, 
38.7, 38.6, 37.9, 37.8, 36.8, 32.5, 32.4, 31.1, 28.5, 20.2, 14.8, 14.7;  MS (electrospray ionization) 
m/z 417.3 (M+H+);  HRMS calcd for C26H29N2O3+ (M+H+) 417.2178, found 417.2164 (100%). 
II.5. (5aS,7S)-3-Methyl-7-(1-(quinolin-4-ylmethylamino)propan-2-yl)-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (4A).  From 1.28 g (4.65 mmol) of amine 10 
and 0.73 g (4.65 mmol) of 4-quinolinecarboxaldehyde (14A), 1.25 g (65% yield) of 4A was 
obtained as a solid.  1H NMR δ 8.88 (d, J = 4.3 Hz, 1 H), 8.14 (d, J = 7.4 Hz, 1 H), 8.12 (d, J = 
7.0 Hz, 1 H), 7.73 (t, J = 7.6 Hz, 1 H), 7.58 (t, J = 7.8 Hz, 1 H), 7.45 (d, J = 4.3 Hz, 1 H), 6.07 (s, 
1 H), 5.70 (s, 1 H), 5.06 – 4.95 (m, 1 H), 4.27 (s, 2 H), 2.75 – 2.67 (m, 1 H), 2.63 – 2.55 (m, 1 
H), 2.44 (d, J = 14.4 Hz, 1 H), 2.19 (s, 3 H), 2.07 – 1.88 (m, 2 H), 1.75 – 1.47 (m, 4 H), 1.30 – 
1.08 (m, 1 H), 0.94 (d, J = 6.6 Hz, 1.5 H, CH3), 0.93 (d, J = 6.6 Hz, 1.5 H, CH3) (2 diastereomers 
at C12); 13C NMR δ 163.4, 163.37, 162.7, 161.7, 150.4, 148.4, 146.0, 132.8, 130.3, 129.3, 127.3, 
126.6, 123.6, 120.1, 109.3, 99.9, 97.5, 79.8, 79.7, 53.9, 53.8, 50.7, 50.7, 39.3, 38.8, 38.6, 38.0, 
37.9, 36.9, 32.5, 32.4, 31.1, 28.6, 20.3, 14.9, 14.8;  MS (electrospray ionization) m/z 417.5 
(M+H+),139.1;  HRMS calcd for C26H29N2O3+ (M+H+) 417.2178, found 417.2162 (100%). 
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II.6. (5aS,7S)-3-Methyl-7-(1-(quinolin-6-ylmethylamino)propan-2-yl)-6,7,8,9-
tetrahydropyrano[4,3-b]chromen-1(5aH)-one (5). From 0.15 g (0.53 mmol) of amine 10 and 
83 mg (0.53 mmol) of 6-quinolinecarboxaldehyde (15), 104 mg (47% yield) of 5 was obtained as 
a solid.  1H NMR 8.87 δ (d, J = 3.9 Hz, 1 H), 8.12 (d, J = 8.2 Hz, 1 H), 8.06 (d, J = 8.6 Hz, 1 H), 
7.76 (s, 1 H), 7.71 (d, J = 9.0 Hz, 1 H), 7.38 (dd, J = 8.4, 4.1 Hz, 1 H), 6.02 (s, 1 H), 5.66 (s, 1 
H), 5.01 (dd, J = 10.9, 4.7 Hz, 1 H), 3.99 (s, 2 H), 2.70 – 2.62 (m, 1 H), 2.55 – 2.46 (m, 1 H), 
2.40 (d, J = 14.1 Hz, 1 H), 2.15 (s, 3 H), 2.05 – 1.88 (m, 2 H), 1.74 – 1.42 (m, 4 H), 1.26 – 1.01 
(m, 1 H), 0.90 (d, J = 6.3 Hz, 1.5 H, CH3), 0.89 (d, J = 6.3 Hz, 1.5 H, CH3) (2 diastereomers at 
C12); 13C NMR δ 163.4, 163.36, 162.7, 161.6, 150.3, 147.7, 137.4, 136.2, 132.7, 132.7, 130.4, 
129.6, 128.3, 126.9, 121.5, 109.2, 99.9, 97.4, 97.4, 79.7, 79.5, 53.5, 52.7, 52.7, 39.2, 38.7, 38.5, 
37.4, 37.3, 36.7, 32.4, 32.3, 31.0, 28.4, 20.2, 14.7, 14.6;  MS (electrospray ionization) m/z 417.5 
(M+H+), 142.0;  HRMS calcd for C26H29N2O3+ (M+H+) 417.2178, found 417.2174 (100%). 
II.7. (5aS,7S)-3-Methyl-7-(1-(quinolin-8-ylmethylamino)propan-2-yl)-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (6).  From 43 mg (0.15 mmol) of amine 10 and 
24 mg (0.15 mmol) of 8-quinolinecarboxaldehyde (16), 34 mg (53% yield) of 6 was obtained as 
a solid.  A mixture of ethanol and THF (2:1) was used as solvent in the reaction.  In the column 
chromatographic separation, the column was deactivated with 2% triethylamine in hexane prior 
to the loading of the crude product.  1H NMR δ 8.87 – 8.83 (m, 1 H), 8.12 (d, J = 8.2 Hz, 1 H), 
7.69 (d, J = 8.2 Hz, 1 H), 7.61 (d, J = 7.0 Hz, 1 H), 7.44 (t, J = 7.4 Hz, 1 H), 7.37 (dd, J = 8.2, 
3.9 Hz, 1 H), 5.99 (s, 1 H),  5.65 (s, 1 H), 5.01 – 4.91 (m, 1 H), 4.30 (s, 2 H), 2.58 (dd, J = 11.7, 
5.8 Hz, 1 H), 2.50 – 2.42 (m, 1 H), 2.35 (d, J = 12.9 Hz, 1 H), 2.13 (s, 3 H), 2.02 – 1.82 (m, 2 H), 
1.69 – 1.38 (m, 4 H), 1.30 – 0.99 (m, 1 H), 0.82 (d, J = 6.2 Hz, 3 H);  13C NMR δ 163.4, 163.35, 
162.7, 161.6, 149.5, 147.0, 136.8, 133.0, 132.9, 129.6, 128.6, 127.5, 126.5, 121.3, 109.2, 109.14, 
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99.9, 97.5, 79.8, 79.7, 53.1, 53.0, 51.7, 51.67, 39.4, 38.5, 38.45, 37.5, 37.4, 36.7, 32.5, 32.4, 31.1, 
28.2, 20.3, 14.7, 14.63;  MS (electrospray ionization) 439.5 (M+Na+), 417.3 (M +H+), 142.1;  
HRMS calcd for C26H29N2O3+ (M+H+) 417.2178, found 417.2173 (100%). 
II.8. (5aS,7S)-3-Methyl-7-(1-((2-methylquinolin-4-yl)methylamino)propan-2-yl)-1H,7H-
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (4B). From 43 mg (0.15 mmol) of 
amine 10 and 26 mg (0.15 mmol) of 2-methyl-4-quinolinecarboxaldehyde (14B), 40 mg (60% 
yield) of 4B was obtained as a solid.  1H NMR δ 8.01 (d, J = 8.6 Hz, 2 H), 7.65 (t, J = 7.6 Hz, 1 
H), 7.47 (t, J = 7.6 Hz, 1 H), 7.31 (s, 1 H), 6.03 (s, 1 H), 5.68 (s, 1 H), 5.04 – 4.94 (m, 1 H), 4.18 
(s, 2 H), 2.73 – 2.63 (m, 1 H), 2.71 (s, 3 H), 2.59 – 2.52 (m, 1 H), 2.41 (d, J = 14.5 Hz, 1 H), 2.16 
(s, 3 H), 2.05 – 1.86 (m, 2 H), 1.75 – 1.44 (m, 4 H), 1.26 – 1.05 (m, 1 H), 0.91 (d, J = 6.6 Hz, 1.5 
H, CH3), 0.90 (d, J = 6.6 Hz, 1.5 H, CH3); 13C NMR δ 163.4, 163.3, 162.7, 161.6, 158.9, 148.0, 
145.8, 132.81, 132.80, 129.3, 129.3, 125.7, 125.4, 123.3, 120.9, 109.2, 99.9, 97.4, 79.7, 79.6, 
53.8, 53.79, 50.6, 50.61, 39.3, 38.7, 38.5, 37.9, 37.8, 36.8, 32.5, 32.3, 31.1, 28.5, 25.5, 20.2, 14.9, 
14.7;  MS (electrospray) 431.4 (M+H+), 144.2;  HRMS calcd for C27H31N2O3+ (M+H+) 
431.2335, found 431.2320 (100%). 
II.9. 4-((2-((5aS,7S)-Methyl-1-oxo-1,5a,6,7,8,9-hexahydropyrano[4,3-b]chromen-7-
yl)propylamino)methyl)quinolin-2-yl)methyl  acetate (4C).  From 43 mg (0.15 mmol) of 
amine 10 and 34 mg (0.15 mmol) of quinolinecarboxaldehyde 14C, 50 mg (66% yield) of 4C 
was obtained as a solid.  A mixture of ethanol and THF (2:1) was used as a solvent for the 
reaction.  1H NMR δ 8.09 (dd, J = 8.2, 3.1 Hz, 2 H), 7.71 (t, J = 7.6 Hz, 1 H), 7.56 (t, J = 7.6 Hz, 
1 H), 7.52 (s, 1 H), 6.05 (s, 1 H), 5.70 (s, 1 H), 5.37 (s, 2 H), 5.06 – 4.96 (m, 1 H), 4.25 (s, 2 H), 
2.75 – 2.67 (m, 1 H), 2.61 – 2.54 (m, 1 H), 2.43 (d, J = 14.0 Hz, 1 H), 2.19 (s, 3 H), 2.18 (s, 3 H), 
2.07 – 1.88 (m, 2 H), 1.73 – 1.48 (m, 4 H), 1.31 – 1.06 (m, 1 H), 0.94 (d, J = 6.6 Hz, 1.5 H, 
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CH3), 0.93 (d, J = 6.6 Hz, 1.5 H, CH3) (2 diastereomers at C12);  13C NMR δ 170.9, 163.4, 
163.4, 162.7, 161.7, 156.0, 147.9, 147.0, 132.8, 130.1, 129.7, 126.8, 126.5, 123.5, 118.5, 109.3, 
99.9, 97.5, 79.8, 79.6, 67.8, 53.9, 53.9, 50.8, 50.8, 39.3, 38.8, 38.7, 38.0, 37.9, 36.9, 32.5, 32.4, 
31.1, 28.6, 21.2, 20.3, 15.0, 14.8;  MS (electrospray ionization) 511.2 (M+Na+), 489.2 (M+H+);  
HRMS calcd for C29H32N2O5Na+ (M+Na+) 511.2209, found 511.2184 (100%). 
II.10. (5aS,7S)-7-(1-((2-(Hydroxymethyl)quinolin-4-yl)methylamino)propan-2-yl)-3-methyl-
6,7,8,9-hexahydropyrano[4,3-b]chromen-1(5aH)-one (4D).  From 43 mg (0.15 mmol) of 
amine 10 and 29 mg (0.15 mmol) of (2-hydroxymethyl)quinoline-4-carboxaldehyde (14D), 42 
mg (61% yield) of 4D was obtained as a solid.  Ethanol was used as a solvent in the reaction.  1H 
NMR δ 8.09 (d, J = 8.2 Hz, 1 H), 8.07 (d, J = 7.8 Hz, 1 H), 7.72 (t, J = 7.6 Hz, 1 H), 7.56 (t, J = 
7.6 Hz, 1 H), 7.35 (s, 1 H), 6.06 (s, 1 H), 5.70 (s, 1 H), 5.06 – 4.97 (m, 1 H), 4.91 (s, 2 H), 4.25 
(s, 2 H), 2.76 – 2.66 (m, 1 H), 2.63 – 2.54 (m, 1 H), 2.43 (d, J = 14.0 Hz, 1 H), 2.19 (s, 3 H), 2.08 
– 1.88 (m, 2 H), 1.77 – 1.47 (m, 4 H), 1.33 – 1.06 (m, 1 H), 0.94 (d, J = 6.6 Hz, 1.5 H, CH3), 
0.93 (d, J = 6.6 Hz, 1.5 H, CH3);  13C NMR δ 163.4, 163.37, 162.7, 161.7, 159.0, 146.9, 146.7, 
132.8, 132.79, 129.6, 129.5, 126.5, 126.4, 123.5, 117.1, 109.3, 99.9, 97.5, 79.8, 79.6, 64.3, 53.9, 
53.86, 50.7, 50.65, 39.3, 38.8, 38.6, 38.0, 37.9, 36.8, 32.5, 32.4, 31.1, 29.9, 28.6, 20.3, 14.9, 
14.8;  MS (electrospray ionization) 469.3 (M+Na+), 447.3 (M+1), 142; HRMS calcd for 
C27H31N2O4+ (M+H+) 447.2284, found 447.2284. 
II.11. (5aS,7S)-7-(1-((2-(1,3,5-Trioxan-2-yl)quinolin-4-yl)methylamino)propan-2-yl)-3-
methyl-6,7,8,9-tetrahydropyrano[4,3-b]chromen-1(5aH)-one (4E). From 102 mg (0.37 mmol) 
of amine 10 and 91 mg (0.37 mmol) of aldehyde 14E, 88 mg (47% yield) of compound 4E was 
obtained as a solid.  Ethanol was used as solvent in the reaction.  1H NMR δ 8.16 (d, J = 8.2 Hz, 
1 H), 8.14 (d, J = 7.6 Hz, 1 H), 7.84 (d, J = 1.6 Hz, 1 H), 7.72 (t, J = 7.6 Hz, 1 H), 7.59 (t, J = 8.1 
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Hz, 1 H), 6.11 (s, 1 H), 6.05 (s, 1 H), 5.69 (s, 1 H), 5.46 – 5.39 (m, 4 H), 5.07 – 4.98 (m, 1 H), 
4.27 (s, 2 H), 2.75 – 2.66 (m, 1 H), 2.63 - 2.54 (m, 1 H), 2.43 (d, J = 14.1 Hz, 1 H), 2.18 (s, 3 H), 
2.07 – 1.87 (m, 2 H), 1.78 – 1.46 (m, 4 H), 1.33 – 1.06 (m, 1 H), 0.92 (d, J = 6.8 Hz, 1.5 H, 
CH3), 0.92 (d, J = 6.8 Hz, 1.5 H, CH3) (2 diastereomers at C12);  13C NMR δ 163.4, 163.37, 
162.7, 161.7, 155.2, 147.7, 147.5, 133.0, 130.5, 129.7, 127.5, 127.3, 123.7, 117.3, 117.2, 109.3, 
102.3, 99.9, 97.5, 93.9, 79.8, 79.7, 54.0, 53.9, 51.0, 51.0, 39.4, 38.6, 38.5, 38.0, 37.9, 36.8, 32.6, 
32.4, 31.2, 28.5, 20.3, 14.9, 14.8;  MS (electrospray ionization) 527.4 (M+Na+), 505.6 (M+H+), 
445.1, 199.3, 139.0;  HRMS calcd for C29H33N2O6+ (M+H+) 505.2339, found 505.2340. 
II.12. (5aS,7S)-3-Methyl-7-(1-((4-methylquinolin-2-yl)methylamino)propan-2-yl)-1H,7H-
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (3B).  From 43 mg (0.15 mmol) of 
amine 10 and 26 mg (0.15 mmol) of 4-methyl-2-quinolinecarboxaldehyde (13B), 35  mg (53% 
yield)  of compound 3B was obtained as a solid.  Ethanol was used as solvent in the reaction.  1H 
NMR δ 8.03 (d, J = 8.1 Hz, 1 H), 7.96 (d, J = 8.2 Hz, 1 H), 7.67 (t, J = 7.4 Hz, 1 H), 7.51 (t, J = 
7.4 Hz, 1 H), 7.27 (s, 1 H),  6.03 (s, 1 H), 5.67 (s, 1 H), 5.12 – 4.97 (m, 1 H), 4.02 (s, 2 H), 2.75 - 
2.60 (m, 1 H), 2.68 (s, 3 H), 2.59 – 2.231  (m, 2 H), 2.16 (s, 3 H), 2.11 – 1.86 (m, 2 H), 1.78 – 
1.39 (m, 4 H), 1.31 – 1.04 (m, 1 H), 0.92 (d, J = 6.4, Hz, 1.5 H), 0.91 (d, J = 6.4, Hz, 1.5 H);  13C 
NMR δ 163.4, 162.7, 161.6, 156.0, 147.7, 144.7, 133.0, 129.6, 129.3, 127.5, 126.0, 123.9, 121.4, 
109.2, 99.9, 97.5, 79.9, 79.7, 56.0, 53.8, 53.7, 39.4, 38.7, 38.5, 38.0, 37.8, 36.8, 32.6, 32.4, 31.2, 
28.5, 20.2, 18.9, 14.9, 14.7.  MS (electrospray ionization) 429.1 (M-1).  HRMS calcd for 
C27H31N2O3+ (M+H+) 431.2335, found 431.2308 (100%). 
II.13. (5aS,7S)-3-Methyl-7-(1-((6-methylquinolin-4-yl)methylamino)propan-2-yl)-1H,7H-
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (4F). From 85 mg (0.31 mmol) of 
amine 10 and 53 mg (0.31 mmol) of 6-methyl-4-quinolinecarboxaldehyde (14F), 82 mg (62% 
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yield) of compound 4F was obtained as a solid.  A mixture of ethanol and THF (2:1) was used as 
a solvent in the reaction.  1H NMR δ 8.78 (d, J = 4.3 Hz, 1 H), 8.01 (d, J = 8.6 Hz, 1 H), 7.85 (s, 
1 H), 7.53 (d, J = 8.6 Hz, 1 H), 7.39 (d, J = 4.3 Hz, 1 H), 6.05 (s, 1 H), 5.69 (s, 1 H), 5.05 – 4.94 
(m, 1 H), 4.21 (s, 2 H), 2.75 – 2.66 (m, 1 H), 2.62 – 2.54 (m, 1 H), 2.56 (s, 3 H), 2.43 (d, J = 14.0 
Hz, 1 H), 2.17 (s, 3 H), 2.07 – 1.88 (m, 2 H), 1.74 – 1.47 (m, 4 H), 1.31 – 1.07 (m, 1 H), 0.94 (d, 
J = 7.0 Hz, 1.5 H, CH3), 0.93 (d, J = 7.0 Hz, 1.5 H, CH3) (2 diastereomers at C12); 13C NMR δ 
163.4, 163.35, 162.7, 161.6, 149.5, 147.0, 145.2, 136.5, 132.8, 131.5, 130.0, 127.2, 122.4, 120.0, 
109.3, 99.9, 97.5, 79.8, 79.7, 53.9, 53.8, 50.7, 39.3, 38.8, 38.7, 38.0, 37.9, 36.9, 32.5, 32.4, 31.2, 
28.6, 22.1, 20.2, 14.9, 14.8;  MS (electrospray ionization) 431.4 (M+1), 156.2, 144.3; HRMS 
calcd for C27H30N2O3Na+ (M+Na+) 453.2154, found 453.2151. 
II.14. (5aS,7S)-3-Methyl-7-(1-((6-methylquinolin-2-yl)methylamino)propan-2-yl)-1H,7H-
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (3C).  From 43 mg (0.15 mmol) of 
amine 10 and 26 mg (0.15 mmol) of 6-methyl-2-quinolinecarboxaldehyde (13C), 37 mg of 
compound 3C (56% yield) was obtained as a solid.  Ethanol was used as a solvent in the 
reaction.  1H NMR δ 8.04 (d, J = 8.2 Hz, 1 H), 7.94 (d, J = 8.6 Hz, 1 H), 7.57 (s, 1 H), 7.53 (dd, J 
= 8.6, 1.6 Hz, 1 H), 7.40 (d, J = 8.6 Hz, 1 H), 6.05 (s, 1 H), 5.69 (s, 1 H), 5.10 – 5.02 (m, 1 H), 
4.08 (s, 2 H), 2.73 – 2.65 (m, 1 H), 2.59 – 2.49 (m, 1 H), 2.53 (s, 3 H), 2.43 (d, J = 14.4 Hz, 1 H), 
2.18 (s, 3 H), 2.10 – 1.93 (m, 2 H), 1.77 – 1.46 (m, 4 H), 1.29 – 1.07 (m, 1 H), 0.94 (d, J = 6.6 
Hz, 1.5 H, CH3), 0.93 (d, J = 6.6 Hz, 1.5 H, CH3) (2 diastereomers at C12); 13C NMR δ 163.5, 
163.4, 162.8, 161.6, 159.1, 146.4, 136.2, 136.1, 133.0, 132.99, 132.0, 128.7, 127.5, 126.7, 120.7, 
109.2, 100.0, 97.5, 79.9, 79.7, 55.9, 53.7, 53.6, 39.4, 38.7, 38.5, 37.9, 37.8, 36.8, 32.6, 32.4, 31.2, 
28.4, 21.7, 20.3, 14.9, 14.7;  MS (electrosprary ionization) 431.4 (M+1), 156.1, 129.2;  HRMS 
calcd for C27H31N2O3+ (M+H+) 431.2335, found 431.2309 (100%). 
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 II.15. 5aS,7S)-7-(1-(Benzo[h]quinolin-4-ylmethylamino)propan-2-yl)-3-methyl-1H,7H-
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (7).  From 51 mg (0.18 mmol) of 
amine 10 and 38 mg (0.18 mmol) of 7,8-benzoquinoline-4-carboxaldehyde (17), 54 mg (62% 
yield) of compound 7 was obtained as a solid.  Ethanol was used as a solvent in the reaction.  1H 
NMR δ 9.32 (d, J = 7.4 Hz, 1 H), 8.96 (d, J = 4.3 Hz, 1 H), 8.03 (d, J = 9.0 Hz, 1 H), 7.92 (d, J = 
7.4 Hz, 1 H), 7.85 (d, J = 9.4 Hz, 1 H), 7.78 – 7.68 (m, 2 H), 7.56 (d, J = 4.7 Hz, 1 H), 6.05 (s, 1 
H), 5.64 (s, 1 H), 5.05 – 4.94 (m, 1 H), 4.30 (s, 2 H),  2.76 – 2.66 (m, 1 H), 2.64 – 2.56 (m, 1 H), 
2.43 (d, J = 14.4 Hz, 1 H), 2.18 (s, 3 H), 2.04 – 1.89 (m, 2 H), 1.76 – 1.46 (m, 4 H), 1.43 – 1.06 
(m, 1 H), 0.95 (d, J = 7.0 Hz, 1.5 H, CH3), 0.93 (d, J = 7.0 Hz, 1.5 H, CH3);  13C NMR δ 163.4, 
162.8, 161.6, 148.8, 146.7, 145.7, 133.4, 132.9, 132.0, 128.3, 127.9, 127.8, 127.3, 125.1, 124.9, 
121.3, 121.1, 109.2, 99.9, 97.5, 79.8, 79.6, 53.8, 53.7, 51.1, 39.2, 38.8, 38.6, 38.0, 37.8, 36.8, 
32.5, 32.4, 31.1, 28.7, 20.3, 15.0, 14.8;  MS (electrospray ionization) m/z 467.6 (M+H+), 192.3;  
HRMS calcd for C30H31N2O3+ (M+H+) 467.2335, found 467.2335 (100%). 
II.16. N-(2-((5aS,7S)-3-Methyl-1-oxo-1,5a,6,7,8,9-hexahydropyrano[4,3-b]chromen-7-
yl)propyl)quinolie-4-carboxamide (8). A mixture of 43 mg (0.15 mmol) of amine 10, 42 mg 
(0.24 mmol) of quinoline-4-carboxylic acid (18), 56 mg (0.36 mmol) of EDC, and 2 mg (0.02 
mmol) of DMAP in 5 mL of dichloromethane was stirred under argon at 25oC for 12 h.  The 
reaction mixture was diluted with 100 mL of dichloromethane, washed with water, and brine, 
dried (MgSO4), concentrated, and column chromatographed on silica gel using a gradient 
mixture of hexane and ethyl acetate as eluant to give 43 mg (65% yield) of compound 8, as a 
solid.  1H NMR δ 8.82 (d, J = 4.3 Hz, 1 H), 8.16 (d, J = 8.6 Hz, 1 H), 8.08 (d, J = 8.6 Hz, 1 H), 
7.73 (t, J = 7.6 Hz, 1 H), 7.57 (t, J = 7.6 Hz, 1 H), 7.34 (d, J = 4.3 Hz, 1 H), 6.72 (br. s, 1 H, 
NH), 5.97 (s, 1 H), 5.68 (s, 1 H), 5.09 – 4.98 (m, 1 H), 3.63 – 3.52 (m, 1 H), 3.42 – 3.29 (m, 1 
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H), 2.43 (d, J = 13.3 Hz, 1 H), 2.14 (s, 4 H), 2.06 – 1.90 (m, 1 H), 1.87 – 1.71 (m, 2 H), 1.71 – 
1.51 (m, 2 H), 1.43 – 1.11 (m, 1 H), 0.99 (d, J = 6.6 Hz, 1.5 H, CH3) 0.98 (d, J = 6.6 Hz, 1.5 H, 
CH3) (2 diastereomers at C12); 13C NMR δ 167.7, 163.5, 162.7, 161.8, 149.9, 148.7, 142.4, 
132.4, 130.2, 129.9, 127.8, 125.4, 124.6, 118.5, 109.4, 99.9, 97.4, 79.6, 79.4, 43.9, 39.2, 38.8, 
38.7, 38.0, 36.9, 32.4, 32.3, 31.1, 28.6, 20.2, 14.5, 14.4;  MS (electrospray ionization) m/z 453.3 
(M + Na+), 431.1 (M+H+);  HRMS calcd for C26H27N2O4+ (M+H+) 431.1971, found 431.1957 
(100%). 
General procedure for the syntheses of compounds 14A, 15, 14E, and 25.13 
II.17.  Quinoline-4-carboxaldehyde (14A).  A solution of 5.0 g (35 mmol) of 4-
methylquinoline (19) and 5.0 g (45 mmol) of SeO2 in toluene under argon was heated to reflux 
for 24 h.  The reaction mixture was diluted with dichloromethane, washed with brine, dried 
(MgSO4), concentrated, and column chromatographed on silica gel using a mixture of hexanes 
and ethyl acetate (4:1) as eluant to give 4.0 g (73% yield) of compound 14A,13 as a solid.  1H 
NMR δ 10.54 (s, 1 H), 9.22 (d, J = 4.3 Hz, 1 H), 9.04 (d, J = 8.6 Hz, 1 H), 8.24 (d, J = 8.2 Hz, 1 
H), 7.84 (t, J = 7.6 Hz, 1 H), 7.81 (d, J = 4.3 Hz, 1 H), 7.76 (t, J = 8.0 Hz, 1 H); 13C NMR δ 
193.1, 150.7, 149.5, 137.0, 130.4, 130.3, 129.6, 126.0, 124.7, 124.1.  MS (electrospray 
ionization) m/z 158.0 (100%) (M+H+), 130.2. 
II.18.  Quinoline-6-carboxaldehyde (15).  From 0.50 g (3.5 mmol) of 6-methylquinoline (20), 
0.12 g (54% yield based on recovered compound 20) of 1513 as a solid and 0.30 g of 20 was 
recovered. 1H NMR δ 10.20 (s, 1 H), 9.05 (dd, J = 4.3, 1.6 Hz, 1 H), 8.35 (s, 1 H), 8.32 (dd, J = 
8.2, 1.9 Hz, 1 H), 8.23 – 8.17 (m, 2 H), 7.52 (dd, J = 8.2, 4.3 Hz, 1 H); 13C NMR δ 191.6, 153.3, 
151.1, 137.6, 134.5, 133.8, 131.0, 127.9, 126.9, 122.4.  MS (electrospray ionization) m/z 157.9 
(100%) (M+H+). 
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II.19.  2-(1,3,5-Trioxan-2-yl)quinoline-4-carboxaldehyde (14E).  From 0.30 g (1.3 mmol) of 
29, 96 mg (35% yield based on recovered 29) of compound 14E was obtained as a solid and 40 
mg of 29 was recovered.  1H NMR δ 10.53 (s, 1 H), 9.08 (dd, J = 8.0, 1.2 Hz, 1 H), 8.26 (dd, J = 
7.8, 0.8 Hz, 1 H), 8.25 (s, 1 H), 7.86 (ddd, J = 7.8, 7.0, 1.6 Hz, 1 H), 7.78 (ddd, J = 7.8, 7.0, 1.6 
Hz, 1 H), 6.21 (s, 1 H), 5.49 – 5.45 (m, 4 H);  13C NMR δ 193.0, 155.8, 148.3, 138.0, 130.7, 
130.2, 130.1, 124.7, 124.3, 124.0, 101.3, 93.8.  MS (electrospray ionization) m/z 268.3 (100%) 
(M+Na+). 
II.20.  4-(1,3,5-Trioxan-2-yl)quinoline-2-carboxaldehyde (25). From 0.70 g (3.0 mmol) of 24, 
0.60 g (81% yield) of 25 as a solid.  The reaction was conducted at 80 °C for 15 h.  1H NMR δ 
10.24 (s, 1 H),  8.32 (d, J = 9.0 Hz, 2 H), 8.31 (s, 1 H), 7.85 (ddd, J = 8.5, 7.1, 1.2 Hz, 1 H), 7.75 
(ddd, J = 8.4, 6.6, 1.2 Hz, 1 H), 6.47 (s, 1 H), 5.51 – 5.46 (m, 4 H);  13C NMR δ 193.5, 152.5, 
148.6, 142.1, 131.3, 130.6, 129.8, 127.0, 124.6, 115.5, 99.1, 93.9.  MS (electrospray ionization) 
m/z 267.9 (100%) (M+Na+), 245.9 (M+H+).  See Experiment II.26. for a direct conversion of 24 
to dialdehyde 26. 
General procedure for the syntheses of compounds 13B, 14F, 13C, 17, 24, and 29. 
II.21.  4-Methylquinoline-2-carboxaldehyde (13B).  To a solution of 0.95 g (8.4 mmol) of 
trifluoroacetic acid and 1.0 g (7.0 mmol) of 4-methylquinoline (19), were added 3.6 mL (28 
mmol) of 70% tert-butyl hydroperoxide, 78 mg (0.28 mmol) of FeSO4•7H2O, 20 mL of 
acetonitrile, and 20 g of trioxane.  The reaction mixture was heated to reflux for 12 h, cooled to 
25 °C, basified with 5% NaOH, and extracted three times with diethyl ether.  The combined 
organic layer was washed with brine, and concentrated.  The residue was diluted with 100 mL of 
10% H2SO4, heated to reflux for 5 h, cooled to 25 °C, basified with 10% NaOH, and extracted 
three times with diethyl ether.  The combined organic layer was washed with brine, dried 
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(MgSO4), concentrated, and column chromatographed on silica gel using a gradient mixture of 
hexane and ethyl acetate as eluant to give 0.38 g (50% yield based on recovered 19) of 13B15,16 
as a solid and 0.37 g of 19 was recovered.  1H NMR δ 10.19 (s, 1 H), 8.24 (d, J = 8.2 Hz, 1 H), 
8.06 (d, J = 8.2 Hz, 1 H), 7.86 (s, 1 H), 7.81 (ddd, J = 8.4, 6.8, 1.2 Hz, 1 H), 7.70 (ddd, J = 8.2, 
7.0, 1.2 Hz, 1 H), 2.78 (s, 3 H);  13C NMR δ 194.3,152.4, 147.9, 146.2, 131.2, 130.3, 130.25, 
129.1, 124.2, 118.1, 19.1.  MS (electrospray ionization) m/z 172.0 (100%) (M+H+). 
II.22.  6-Methylquinoline-4-carboxaldehyde (14F) and 6-methylquinoline-2-carboxaldehyde 
(13C).  From 1.5 g (10.5 mmol) of 6-methylquinoline (20), 0.24 g (17% yield based on 
recovered 20) of 14F and 0.23 g (16% yield) of 13C20 as solids, and 0.31 g of 20 was recovered. 
Compound 14F:  1H NMR δ 10.51 (s, 1 H), 9.14 (d, J = 4.3 Hz, 1 H), 8.83 (s, 1 H), 8.12 (d, J = 
8.6 Hz, 1 H), 7.77 (d, J = 4.3 Hz, 1 H), 7.67 (dd, J = 8.6, 1.9 Hz, 1 H), 2.63 (s, 3 H); 13C NMR δ 
192.8, 149.2, 147.7, 139.6, 135.8, 132.2, 129.4, 125.8, 123.7, 123.1, 22.0;  MS (electrospray 
ionization) m/z 172.0 (100%) (M+H+), 144.1. 
Compound 13C:  1H NMR δ 10.21 (s, 1 H), 8.21 (d, J = 8.2 Hz, 1 H), 8.14 (d, J = 9.4 Hz, 1 H), 
8.00 (d, J = 8.6 Hz, 1 H), 7.67 (s, 1 H), 7.66 (dd, J = 8.0, 2.0 Hz, 1 H), 2.59 (s, 3 H); 13C NMR δ 
194.0, 152.2, 146.8, 139.9, 136.8, 133.1, 130.4, 130.3, 126.9, 117.7, 22.1.  MS (electrospray 
ionization) m/z 172.0 (100%) (M+H+). 
II.23.  Benzo[h]quinoline-4-carboxaldehyde (17).  From 0.50 g (2.79 mmol) of 
benzo[h]quinoline (30), 90 mg (18% yield based on recovered 30) of 1722 as a solid and 85 mg 
of 30 was recovered.  1H NMR δ 10.50 (s, 1 H), 9.26 (d, J = 7.8 Hz, 1 H), 9.16 (d, J = 4.3 Hz, 1 
H), 8.74 (d, J = 9.4 Hz, 1 H), 7.94 – 7.84 (m, 2 H), 7.80 – 7.68 (m, 3 H); 13C NMR δ 192.9, 
148.9, 147.8, 136.5, 133.3, 131.2, 130.9, 129.0, 127.9, 127.7, 125.0, 124.9, 122.9, 120.8.  MS 
(electrospray ionization) m/z 208 (M+H+), 186.2. 
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II.24.  2-Methyl-4-(1,3,5-trioxan-2-yl)quinoline (24).15,16  From 10.0 g (70 mmol) of 2-
methylquinoline (23), 5.3 g (50% yield based on recovered 23) of 24 and 3.5 g of 23 was 
recovered.  1H NMR δ 8.05 (d, J = 8.6 Hz, 2 H), 7.66 (t, J = 7.8 Hz, 1 H), 7.55 (s, 1 H), 7.49 (t, J 
= 7.8 Hz, 1 H), 6.33 (s, 1 H), 5.44 – 5.36 (m, 4 H), 2.73 (s, 3 H); 13C NMR δ 159.0, 148.4, 140.4, 
129.4, 129.39, 126.1, 123.6, 123.3, 119.5, 98.8, 93.8, 25.5.   MS (electrospray ionization) m/z 
232.2 (M+H+), 172.0, 144.1. 
II.25.  4-Methyl-2-(1,3,5-trioxan-2-yl)quinoline (29).15,16  From 5.0 g (35 mmol) of 4-
methylquinoline (19), 3.0 g (43% yield based on recovered 19) of 29 and 0.24 g (4% yield) of 
13B, along with 0.70 g of 19.  1H NMR δ 8.11 (d, J = 8.2 Hz, 1 H), 7.92 (d, J = 8.5 Hz, 1 H), 
7.67 (t, J = 7.6 Hz, 1 H), 7.61 (s, 1 H), 7.52 (t, J = 7.6 Hz, 1 H), 6.04 (s, 1 H), 5.41 – 5.33 (m, 4 
H), 2.66 (s, 3 H); 13C NMR δ 154.9, 147.0, 145.9, 130.1, 129.5, 128.4, 127.0, 123.7, 118.9, 
102.2, 93.7, 18.9.  MS (electrospray ionization) m/z 270.2 (M+K+), 254.1 (M+Na+), 232.2 
(M+H+), 172.0. 
II.26.  2-Methylquinoline-4-carboxaldehyde (14B).15,16 From 0.50 g (2.2 mmol) of 24, 0.29 g 
(79% yield) of 14B was obtained as a solid.  1H NMR δ 10.49 (s, 1 H), 8.97 (dd, J = 8.6, 1.2 Hz, 
1 H), 8.13 (d, J = 8.6 Hz, 1 H), 7.80 (ddd, J = 8.3, 7.0, 1.6 Hz, 1 H), 7.70 (s, 1 H), 7.68 (ddd, J = 
8.5, 6.8, 1.2 Hz, 1 H), 2.88 (s, 3 H); 13C NMR δ 193.0, 159.2, 149.0, 137.0, 130.2, 129.2, 128.3, 
127.2, 124.3, 122.2, 25.3.   MS (electrospray ionization) m/z 172.0 (100%) (M+H+). 
II.27.  Quinoline-2,4-dicarboxaldehyde (26).  From 0.70 g of 24, 0.38 g (68% yield in two 
steps) of compound 2623 was obtained as a solid. Hydrolysis with 2 N HCl was used.  1H NMR δ 
10.53 (s, 1 H), 10.28 (s, 1 H), 9.11 (dd, J = 8.2, 1.2 Hz, 1 H), 8.40 (s, 1 H), 8.35 (dd, J = 8.0, 1.4 
Hz, 1 H), 7.92 (ddd, J = 8.2, 7.0, 1.6 Hz, 1 H), 7.87 (ddd, J = 8.4, 7.0, 1.6 Hz, 1 H); 13C NMR δ 
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192.9, 192.7, 153.0, 149.2, 138.1, 132.3, 131.3, 131.2, 125.6, 125.2, 122.8.  MS (electrospray 
ionization) m/z 186.1 (M+H+), 172.0. 
II.28.  Quinoline-8-carboxaldehyde (16).  A solution of 0.50 g (3.5 mmol) of 8-
methylquinoline (21), 1.87 g (10.5 mmol) of N-bromosuccinamide (NBS), and 50 mg (0.3 mmol) 
of azobisisobutyronitrile (AIBN) in dichloroethane was refluxed under argon for 30 h.  The 
reaction mixture was diluted with 150 mL dichloromethane, washed three times with 2 N NaOH, 
and brine, dried (MgSO4), and concentrated. The residue was refluxed in 50 mL of water for 4 h, 
cooled to 25 °C, diluted with 50 mL of 2 N NaOH, and extracted three times with diethyl ether. 
The combined organic layer was washed with brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluant to 
give 0.20 g (37% yield) of 1614 and 0.30 g (53% yield) of 2224 as solids.  Compound 22 was 
converted to compound 16 by treating with IBX and DMSO in 79 % yield.  Compound 16: 1H 
NMR δ 11.45 (s, 1 H), 9.04 (dd, J = 4.3, 1.9 Hz, 1 H), 8.32 (dd, J = 7.0, 1.6 Hz, 1 H), 8.24 (dd, J 
= 8.4, 1.8 Hz, 1 H), 8.08 (dd, J = 8.2, 1.6 Hz, 1 H), 7.67 (t, J = 7.6 Hz, 1 H), 7.51 (dd, J = 8.4, 
4.1 Hz, 1 H); 13C NMR δ 192.8, 151.5, 147.8, 136.5, 134.4, 131.9, 129.5, 128.5, 126.4, 122.0.  
MS (electrospray ionization) m/z 158.0 (M+H+), 128.1. 
Compound 22:  1H NMR δ 8.77 (dd, J = 3.9, 1.2 Hz, 1 H), 8.07 (dd, J = 8.2, 1.2 Hz, 1 H), 7.65 
(d, J = 8.2 Hz, 1 H), 7.55 (d, J = 7.0 Hz, 1 H), 7.40 (t, J = 7.6 Hz, 1 H), 7.32 (dd, J = 8.2, 4.3 Hz, 
1 H), 5.20 (s, 2 H);  13C NMR δ 149.0, 146.8, 138.2, 136.7, 128.3, 127.5, 127.3, 126.4, 121.1, 
64.2.  MS (electrospray ionization) m/z 160.3 (M+H+), 142.0, 141.1. 
II.29.  2-(Hydroxymethyl)quinoline-4-carboxaldehyde (14D).  To a solution of 0.30 g (1.62 
mmol) of 26 in 15 mL of dichloromethane and ethanol (3:1) at 0 °C under argon, was added 15 
mg (0.40 mmol) of NaBH4, and the solution was stirred for 1 h.  The reaction mixture was 
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diluted with 50 mL of brine, extracted twice with dichloromethane, dried (MgSO4), concentrated, 
and column chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate 
as eluant to give 73 mg (32% yield) of 14D, 81 mg (35% yield) of 27, and 38 mg (16% yield) of 
2825 along with 72 mg of recovered 26.  Compound 14D:  1H NMR δ 10.53 (s, 1 H), 9.00 (dd, J 
= 8.4, 1.0 Hz, 1 H), 8.20 (d, J = 8.2 Hz, 1 H), 7.84 (ddd, J = 8.6, 7.0, 1.6 Hz, 1 H), 7.75 (s, 1 H), 
7.73 (ddd, J = 8.6, 7.0, 1.6 Hz, 1 H), 5.06 (s, 2 H); 13C NMR δ 192.8, 159.7, 148.1, 137.8, 130.7, 
129.4, 129.1, 124.7, 123.8, 123.5, 64.5.  MS (electrospray ionization) m/z 188.3 (M+H+), 128.2, 
115.2. 
Compound 27:  1H NMR δ 10.24 (s, 1 H), 8.30 (d, J = 8.6 Hz, 1 H), 8.19 (s, 1 H), 8.05 (dd, J = 
8.2, 0.8 Hz, 1 H), 7.85 (ddd, J = 8.5, 6.9, 1.4 Hz, 1 H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1 H), 5.29 
(d, J = 0.8 Hz, 2 H); 13C NMR δ (CDCl3 and DMSO-d6) δ 193.1, 151.6, 148.9, 146.7, 130.1, 
129.2, 128.3, 126.8, 122.5, 113.4, 59.7.  MS (electrospray ionization) m/z 188.3 (100%) (M+H+), 
115.1. 
Compound 28:  1H NMR δ 8.12 (d, J = 9.0 Hz, 1 H), 7.94 (d, J = 8.2 Hz, 1 H), 7.75 (ddd, J = 8.4, 
6.8, 1.2 Hz, 1 H), 7.58 (ddd, J = 8.4, 7.0, 1.2 Hz, 1 H), 7.46 (s, 1 H), 5.25 (d, J = 3.5 Hz, 2 H), 
4.93 (d, J = 3.9 Hz, 2 H); 13C NMR (DMSO-d6) δ 162.2, 148.0, 146.5, 129.1, 128.9, 125.8, 
124.6, 123.3, 115.7, 65.0, 59.8.  MS (electrospray ionization) m/z 190.2 (100%) (M+H+). 
II.30.  (4-Formylquinolin-2-yl)methyl acetate (14C).  To a mixture of 50 mg (0.27 mmol) of 
14D, 5 mg (0.05 mmol) of ZnO in 8 mL of dichloromethane under argon, was added 0.28 g (2.7 
mmol) of acetic anhydride.  The reaction mixture was stirred at 25oC for 2 h, diluted with 100 
mL of dichloromethane, washed with brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel to give 52 mg (85% yield) of compound 14C as a solid.  1H NMR 
δ 10.53 (s, 1 H), 8.99 (d, J = 8.2 Hz, 1 H), 8.18 (d, J = 8.6 Hz, 1 H), 7.87 (s, 1 H), 7.82 (t, J = 7.6 
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Hz, 1 H), 7.73 (t,  J = 8.2 Hz, 1 H), 5.48 (s, 2 H), 2.23 (s, 3 H); 13C NMR δ 192.9, 170.8, 156.8, 
149.0, 137.8, 130.7, 130.0, 129.6, 124.5, 124.5, 123.5, 67.2, 21.1.  MS (electrospray ionization) 
m/z 230.1 (M+H+), 216.5. 
Bioactivity assay of pyranobenzopyrone compounds. 
The antiviral effects of each compound were examined in NV replicon-harboring cells (HG23 
cells). The detailed procedures for studying the antiviral effects using HG23 cells were reported 
elsewhere. Briefly, One-day old, 80 - 90% confluent HG23 cells were treated with varying 
concentrations of each compound (0 [mock-DMSO] - 10 µM) to examine their effects on the 
replication of NV.  At 48 hrs of treatment, the NV genome was analyzed with real time qRT-
PCR. The ED50 of each compound for NV genome levels was determined at 48 hrs post-
treatment. HG23 cells were also treated with varying concentrations (0 [mock-DMSO] - 200 
µM) of each compound to assess the cytotoxic effects.  Cell cytotoxicity assay kit (Promega, 
Madison, WI) was used to calculate the median toxic dose (TD50) at 48 hrs of treatment. 
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AP9-105-FR6
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
3.822.592.272.522.002.382.351.810.862.140.940.930.93
N N S
O O
H
Cl
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AP9-105-FR6-7-C13
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AP9-123-FR12
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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5.5317.893.754.042.003.031.884.011.992.042.03
N N S
O O
H
TC17 
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AP9-123-FR12-C13
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20
Chemical Shift (ppm)
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KP-10-20-FRAC10
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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2.862.291.742.070.920.891.060.95
TC 18
CN
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KP-10-20-DP-C13
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
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AP9-127-FR4-12
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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3.985.081.972.151.902.002.091.860.931.131.011.03
N N S
O O
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AP9-127-FR4-12-C13
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20
Chemical Shift (ppm)
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SHH-1-42-RECOLUMN-FR-8-9
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SHH-1-42-RECOLUMN-FR-8-9-C13
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